Enanta Pharmaceuticals News and Activities
Presence
Enanta Pharmaceuticals develops small molecule medicines for viral and immune-related diseases. It provides drug discovery, clinical development, and treatment candidates for patients, healthcare providers, and pharmaceutical partners.
Enanta Pharmaceuticals products and services overview:
- Antiviral medicines
- Drug discovery
- Clinical development
- Liver disease therapies
- Respiratory therapies
- Immune disease therapies
Revenue: ~$69 million
Employees: 140
Headquarters: Watertown, United States (USA)
Enanta Pharmaceuticals is one of the...
Enanta Pharmaceuticals is a company listed under the stock ticker ENTA (US).
Acquisition, funding and merger involving Enanta Pharmaceuticals.
- Enanta Pharmaceuticals has just announced a $50 Million fundraising (posted on October 20 2025).
Executives
View the org chart displaying its 28 main executives
Most searched biographies at Enanta Pharmaceuticals
- Jay Luly, President, Chief Executive Officer and Director
- Terry Vance, Director
- Kristine Peterson, Director
Create your alert
to follow the executive moves at Enanta Pharmaceuticals.
Pharmaceuticals
Enanta Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Enanta Pharmaceuticals
- Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022 | Enanta Pharmaceuticals, Inc.
- Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19 | Enanta Pharmaceuticals, Inc.
- Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer | Enanta Pharmaceuticals, Inc.
- Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 | Enanta Pharmaceuticals, Inc.
- Enanta Pharmaceuticals to Participate in Two Investor Conferences in June | Enanta Pharmaceuticals, Inc.
- Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV) | Enanta Pharmaceuticals, Inc.
- Press Releases | Enanta Pharmaceuticals, Inc.
- Press Releases | Enanta Pharmaceuticals, Inc.
- Press Releases | Enanta Pharmaceuticals, Inc.
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET | Enanta Pharmaceuticals, Inc.
- View more press releases Close
Social media about Enanta Pharmaceuticals
- Enanta Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Enanta Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
